Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume 233, Issue 8, Pages 5613-5622Publisher
WILEY
DOI: 10.1002/jcp.26273
Keywords
colorectal cancer; immune responses; inflammation; signaling pathway; toll like receptor
Categories
Funding
- Biotechnology Development Council of the Islamic Republic of Iran [960208]
- National Institute for Medical research Development [958739]
Ask authors/readers for more resources
Toll like receptor (TLR) signaling is involved in activating innate and adaptive immune responses and plays a critical role in inflammation-induced diseases such as colorectal cancer (CRC). Dysregulation of this signaling pathway can result in disturbance of epithelial layer hemostasis, chronic inflammatory, excessive repair responses, and development of CRC. There is now substantial evidence for the benefit of targeting of this pathway in cancer treatment, and several agents have been approved, such as BCG (Bacillus Calmette Guerin), MPL (monophosphoryl lipid A) and imiquimod. This review summarizes the current knowledge about the different functions of TLRs on tumor cells and their application in cancer therapy with particular emphasis on recent preclinical and clinical research in treatment of CRC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available